AI-driven De novo Design of GPC3-binding Macrocycles as Radiotracers for Hepatic Carcinoma (EANM 2026) - Sep 29, 2026 - Abstract #OP-022; Pres time: Oct 18, 2026; 08:00 AM - 09:30 AM; Location: Hall E2; "The clinical approval of 68Ga/64Cu/177Lu-Dotatate (targeting somatostatin receptor, SSTR) highlights the great clinical transformation potential of peptide-conjugated nuclear drugs... This study successfully developed and validated the feasibility and effectiveness of AI-assisted de novo design for GPC3-targeted macrocycles as radiotracers. A total of 1,000 high-binding-potential GPC3-targeting sequences were identified, and the top three peptides were extensively validated. SPR confirmed their Kd values as 9.45x10−5 M, 1.35x10−5 M, and 2.42x10−5 M, respectively."
Hepatocellular Cancer • Oncology • Solid Tumor • GPC3 • SSTR
|